Search company, investor...
Centrexion Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Debt | Alive

Total Raised


Last Raised

$29.14M | 4 mos ago

About Centrexion Therapeutics

Centrexion Therapeutics is focused on developing new treatments for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm. The company was founded in 2013 and is based in Boston, Massachusetts.

Centrexion Therapeutics Headquarters Location

200 State Street 6th Floor

Boston, Massachusetts, 02109,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Centrexion Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Centrexion Therapeutics is included in 2 Expert Collections, including Game Changers 2018.


Game Changers 2018

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Centrexion Therapeutics Patents

Centrexion Therapeutics has filed 43 patents.

The 3 most popular patent topics include:

  • Analgesics
  • Fluoroarenes
  • Amines
patents chart

Application Date

Grant Date


Related Topics




Prodrugs, Analgesics, Fluoroarenes, Piperidines, Glucocorticoids


Application Date


Grant Date



Related Topics

Prodrugs, Analgesics, Fluoroarenes, Piperidines, Glucocorticoids



Latest Centrexion Therapeutics News

5AM, Avidity, Fidelity lead $100M infusion into next-gen, targeted complement approach

May 3, 2022

Amber Tong Senior Editor When the FDA first ap­proved Alex­ion’s Soliris — then eculizum­ab — in 2007, ex­perts cel­e­brat­ed how the first-of-its-kind drug trans­formed the way physi­cians could treat a rare dis­ease called parox­ys­mal noc­tur­nal he­mo­glo­bin­uria. As Soliris racked up more land­mark OKs, the C5 in­hibitor al­so be­came a wild­ly suc­cess­ful fran­chise for the com­pa­ny, spurring block­buster sales that led to a fol­low-on drug and a $39 bil­lion buy­out by As­traZeneca while in­spir­ing new play­ers to jump in­to the com­ple­ment space. Di­anthus Ther­a­peu­tics be­lieves it can make an even big­ger leap than what’s been pro­posed to date — and the start­up is tak­ing the wraps off a $100 mil­lion Se­ries A as it ex­plains the mis­sion. “This field is ripe for pa­tient cen­tric in­no­va­tion and im­prove­ments,” CEO Mari­no Gar­cia told End­points News. Sim­rat Rand­hawa With ba­sic un­der­stand­ing of how dys­reg­u­la­tion of the com­ple­ment path­way trig­gered the com­ple­ment cas­cade and au­toim­mune dis­or­ders, the first-gen­er­a­tion prod­ucts “hit where they could,” CMO Sim­rat Rand­hawa said. The orig­i­nal C5 in­hibitors proved high­ly ef­fec­tive in tam­ing down the prob­lem­at­ic im­mune re­ac­tion, but they al­so shut down a lot else, in­clud­ing the im­mune re­ac­tions one needs to fend off for­eign at­tacks. As a re­sult, the drug la­bels came with boxed warn­ings about life-threat­en­ing bac­te­r­i­al in­fec­tions. As the sci­ence evolves — and it’s still evolv­ing — sci­en­tists have un­earthed new ways of ap­proach­ing this part of the in­nate im­mune sys­tem. For in­stance, Di­anthus’s lead com­pound is de­signed to se­lec­tive­ly hit the ac­tive forms of C1s in or­der to on­ly tar­get the clas­si­cal com­ple­ment path­way — one of three path­ways that trig­ger the com­ple­ment cas­cade. “What we’re try­ing to pro­vide is pret­ty much the most tar­get­ed ap­proach to a com­ple­ment in­hibitor that is avail­able,” Rand­hawa said. Oth­er than po­ten­tial­ly be­ing safer, the biotech hopes that the se­lec­tiv­i­ty will al­so mean that it will need to de­liv­er a lot less an­ti­body than the first-gen­er­a­tion com­ple­ment in­hibitors, lend­ing it­self to sub­cu­ta­neous self-ad­min­is­tra­tion. Gar­cia not­ed that Di­anthus worked with a part­ner to ex­plore half-life ex­ten­sion tech­nolo­gies that made the an­ti­bod­ies last even longer. With the team of 15 scat­tered across the US — the in­com­ing head of qual­i­ty will be work­ing out of Ohio, while the head of clin­i­cal op­er­a­tions re­sides in Seat­tle and the head of tech ops re­ports from the Philadel­phia area — the com­pa­ny hopes to be in the clin­ic by the end of the year. Lon­nie Moul­der’s Tel­lus BioVen­tures pro­vid­ed the ini­tial fund­ing along­side Fair­mount, while Ven­rock helped with the seed. 5AM Ven­tures, Avid­i­ty Part­ners and Fi­deli­ty led the round, with par­tic­i­pa­tion from Wed­bush Health­care Part­ners. Al­though Di­anthus has no wet labs, it hopes to lever­age its net­work of tech­ni­cal ex­perts in be­com­ing a next-gen leader in com­ple­ment ther­a­pies — an am­bi­tion hint­ed in its name, which com­bines the Greek words for god (“dios”) and flower (“an­thus”). “The whole idea was that the an­thus flower was cre­at­ed by Zeus to sort of sur­pass the beau­ty and the scent of the lily,” Gar­cia said. “And I mean, it’s a great sym­bol for the com­pa­ny, be­cause es­sen­tial­ly, that’s what we’re try­ing to do.” AUTHOR John Carroll Editor & Founder Stymied by Medicare and forced to admit the end of its once sky-high hopes in the controversial Alzheimer’s medicine Aduhelm, Biogen announced this morning that CEO Michel Vounatsos is being replaced as the big biotech restructures the pipeline, hunts deals and continues to cut costs with layoffs and more. Vounatsos became a lightning rod for intense criticism of the Aduhelm fiasco as Biogen did a sudden about-face and sought an FDA approval after initially flagging a defeat in pivotal studies. Surprisingly, the FDA group under Billy Dunn offered an accelerated approval despite doubts about its efficacy and safety. And the drug failed to gain any traction, with vanishing expectations after Medicare restricted coverage to a small minority of potential patients. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Last week I invited 4 deeply experienced biopharma execs to gather for an hour to discuss what they’ve learned over the years about developing drugs. What were the key lessons that they’ve taken into new endeavors? And what did they shed along the way? Tectonic CEO Alise Reicin, an experienced Merck vet who had a senior role in developing Keytruda, joined GV exec David Schenkein, who founded Agios, along with Kite founder and current Allogene chair Arie Belldegrun and former Gilead CSO, now Kronos founder, Norbert Bischofberger. It was a great conversation, which you can follow along here. The transcript has been edited for style and brevity. — John Carroll Premium subscription required Jason Mast Editor Vertex thinks it has enough data to progress its experimental stem cell therapy for type 1 diabetes. The FDA has other thoughts. The large biotech announced Monday that the agency put a hold on the clinical trial for the program, which grabbed “ cure ” headlines last year after Vertex released promising data from the first patient dosed in the study. The experimental treatment is designed to replace the insulin-producing cells T1D patients lose with lab-grown insulin-producing cells. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Max Gelman Senior Editor Four years after his sister pleaded guilty to stealing trade secrets from GlaxoSmithKline, a Swiss scientist will join her behind bars after prosecutors secured a conviction in a long-running case Monday. Gongda Xue was convicted by a federal jury of participating in a conspiracy to rob the pharma giant of confidential information to start his own biotech companies with his sister, Yu Xue, the Department of Justice announced Monday. Gongda Xue is the fifth person to be either convicted or plead guilty in the case, and could face up to 10 years in prison. Read More April 29, 2022 08:56 AM EDT Kyle LaHucik Associate Editor The lead drug at Centrexion Therapeutics — a biotech helmed by former Pfizer CEO Jeff Kindler and chaired by Celgene co-founder Sol Barer — has flunked a Phase III test in osteoarthritis knee pain, Endpoints News has learned. Sol Barer A second Phase III trial for the drug also failed to meet its primary endpoint, the company confirmed to Endpoints. Centrexion never planned to issue a press release disclosing the failed studies, but does plan to “submit the data for publication in a peer reviewed medical journal,” according to an emailed statement from a spokesperson. The Boston biotech might also still package up the drug’s results and send it to the FDA’s doorsteps. Three patients died in the treatment arms across the two trials. It’s a blow to the company’s pipeline, as Centrexion had touted CNTX-4975’s potential for a market debut in 2022, with FDA fast track designation already in hand, when it thought about going public in 2018. The IPO never happened despite another eye toward Nasdaq in 2019. The company has not provided an update on its pipeline, financing or general status since disclosing it raised $40.5 million in October 2020. Centrexion had attempted to quietly leave behind the first Phase III flop, with the only disclosure coming in the form of an update on the database on April 8. A press release has not been issued. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Within weeks of Sierra Oncology revealing it had taken a failed Gilead JAK inhibitor and turned it into a Phase III success, GlaxoSmithKline swooped in for a piece of the potential earnings, should the drug, momelotinib, receive an FDA nod. At first, the idea was a strategic partnership. But once GSK commercial chief Luke Miels was introduced to Sierra CEO Stephen Dilly, that changed. Miels delivered a non-binding acquisition proposal of $46 cash per share on March 8. The offer inflated to $51 per share three days later, and eventually reached the final bid of $55 on April 2, according to a background of the eventual merger agreement, revealed in a Monday SEC filing . Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,100+ biopharma pros reading Endpoints daily — and it's free. SIGN UP

Centrexion Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Centrexion Therapeutics Rank

  • When was Centrexion Therapeutics founded?

    Centrexion Therapeutics was founded in 2013.

  • Where is Centrexion Therapeutics's headquarters?

    Centrexion Therapeutics's headquarters is located at 200 State Street, Boston.

  • What is Centrexion Therapeutics's latest funding round?

    Centrexion Therapeutics's latest funding round is Debt.

  • How much did Centrexion Therapeutics raise?

    Centrexion Therapeutics raised a total of $178.26M.

  • Who are the investors of Centrexion Therapeutics?

    Investors of Centrexion Therapeutics include New Enterprise Associates, Quan Capital, Kite Pharma, Concord Health Partners, InterWest Partners and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.